Icahn Gets Wish With Departure Of ImClone’s Kies, But Will Door Open To Him?
This article was originally published in The Pink Sheet Daily
Executive Summary
Billionaire and his allies hold 40% of the biotech’s board, possibly leading to further changes.
You may also be interested in...
ImClone Board Members Demand Control Premium From Icahn
Latest salvo from Icahn prompts board to ask shareholders to reject billionaire’s demands.
ImClone Board Members Demand Control Premium From Icahn
Latest salvo from Icahn prompts board to ask shareholders to reject billionaire’s demands.
ImClone Leadership Battle Intensifies With Calls For Removal Of Six Directors
Carl Icahn wants the chairman and interim CEO removed; CFO departs.